# UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD PAR PHARMACEUTICAL, INC., and LUPIN LTD. and LUPIN PHARMACEUTICALS, INC., **Petitioners** v. HORIZON THERAPEUTICS, INC., Patent Owner Case IPR2015-01117\*

Patent 8,642,012


### PATENT OWNER'S MOTION TO EXCLUDE EVIDENCE

<sup>\*</sup> Case IPR2015-00283, instituted on a petition filed by Lupin Ltd. and Lupin Pharmaceuticals, Inc., has been joined with this proceeding.



## **TABLE OF CONTENTS**

I.	INTI	RODUCTION AND RELIEF REQUESTED	1
II.	PRO	CEDURAL POSTURE AND BACKGROUND	2
IV.	RE-EXAMINATION TESTIMONY OUTSIDE THE SCOPE OF DR. SONDHEIMER'S CROSS-EXAMINATION TESTIMONY SHOULD BE EXCLUDED		
	A.	Re-Examination Testimony Concerning Dr. Sondheimer's Background and Experience Treating UCD Patients Should Be Excluded	4
	В.	Re-Examination Testimony Concerning Dr. Sondheimer's Definition of a Person of Ordinary Skill Should Be Excluded	6
	C.	Re-Examination Testimony Concerning <i>Fernandes</i> is Outside the Scope of Dr. Sondheimer's Cross-Examination Testimony and Should Be Excluded	7
	D.	Re-Examination Testimony Concerning Typical Gelatin Capsule Volume, the Density of Sodium Phenylbutyrate, and Calculation of the Amount of Sodium Phenylbutyrate Dosed in Brusilow '91 Should Be Excluded	9
	E.	Re-Examination Testimony Directed to the Relevant Time Period for a POSA's Evaluation of Alleged Prior Art Regarding the Rate of Conversion of PAA to PAGN Should Be Excluded	10
	F.	Re-Examination Testimony Concerning Table 11.9 of <i>Blau</i> Should Be Excluded	11
	G.	Exhibits 1031-1033 Should be Excluded	12
17	CON	ICLUSION	15



# **TABLE OF AUTHORITIES**

## **Cases**

Corning Gilbert Inc. v. PPC Broadband, Inc., IPR2013-00346, Paper 48 (PTAB June 23, 2014)	4
Rules	
Federal Rule of Evidence 403	14
Federal Rule of Evidence 901	14
Regulations	
37 C.F.R. § 42.53(d)(5)(ii)	4, 14
37 C.F.R. § 42.64	1
37 C.F.R. § 42.64(a)	2
37 C.F.R. § 42.64(c)	2, 3



### I. INTRODUCTION AND RELIEF REQUESTED

Pursuant to 37 C.F.R. § 42.64 and the Board's Scheduling Order, Patent Owner moves to exclude portions of the re-examination testimony of Dr. Neal Sondheimer elicited at his March 10-11, 2016 deposition ("the Sondheimer Deposition," Ex. 2012), because such testimony is outside the scope of Dr. Sondheimer's cross-examination testimony and/or Dr. Sondheimer's direct testimony. Patent Owner also moves to exclude documents offered by Petitioner during re-examination of Dr. Sondheimer as outside the scope of his cross-examination testimony, untimely, irrelevant, and/or lacking foundation and/or authenticity. Petitioner should be precluded from using such documents and the portions of Dr. Sondheimer's testimony identified below at any hearing or in any paper such as, without limitation, a brief, motion, or observation on cross-examination.

Specifically, Patent Owner moves to exclude the following portions of Dr. Sondheimer's re-examination testimony in Exhibit 2012 as well as the documents not previously of record but offered by Petitioner as Exhibits 1031-1033:

- 218:17-224:19;
- 269:15-283:14;
- 225:1-231:1;
- 242:2-242:16;



- 243:15-244:19;
- 249:22-251:6;
- 252:10-254:14;
- 259:5-260:9;
- 261:7-265:2;
- 266:14-267:6; and
- 289:9-21.

Patent Owner's objections to the testimony that is the subject of this Motion are included in the citations referenced above.

### II. PROCEDURAL POSTURE AND BACKGROUND

To preserve its right to exclude evidence based on objections timely made as required by 37 C.F.R. § 42.64(c), Patent Owner is filing this motion seeking to exclude certain deposition testimony and documents offered at the Sondheimer Deposition because such testimony and documents are directed to matters outside of the scope of Dr. Sondheimer's cross-examination testimony and his direct testimony. As required by 37 C.F.R. § 42.64(a), Patent Owner raised timely objections during the Sondheimer Deposition, and therefore preserved its right to seek the exclusion of such testimony and the use of such documents.

In its Reply (Paper No. 0030), Petitioner has not attempted to rely upon the portions of Dr. Sondheimer's deposition transcript or the documents Patent Owner



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

